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As spinal fusions require large volumes of bone graft, different bone graft substitutes are being
investigated as alternatives. A subclass of calcium phosphate materials with submicron surface
topography has been shown to be a highly effective bone graft substitute. In this work, a com-
mercially available biphasic calcium phosphate (BCP) with submicron surface topography
(MagnetOs; Kuros Biosciences BV) was evaluated in an Ovine model of instrumented posterolat-
eral fusion. The material was implanted stand-alone, either as granules (BCPgranules) or as granules
embedded within a fast-resorbing polymeric carrier (BCPputty) and compared to autograft bone
(AG). Twenty-five adult, female Merino sheep underwent posterolateral fusion at L2-3 and L4-5
levels with instrumentation. After 6, 12, and 26 weeks, outcomes were evaluated by manual pal-
pation, range of motion (ROM) testing, micro-computed tomography, histology and histomorpho-
metry. Fusion assessment by manual palpation 12 weeks after implantation revealed 100%
fusion rates in all treatment groups. The three treatment groups showed a significant decrease in
lateral bending at the fusion levels at 12 weeks (P < 0.05) and 26 weeks (P < 0.001) compared to
the 6 week time-point. Flexion-extension and axial rotation were also reduced over time, but sta-
tistical significance was only reached in flexion-extension for AG and BCPputty between the 6 and
26 week time-points (P < 0.05). No significant differences in ROM were observed between the
treatment groups at any of the time-points investigated. Histological assessment at 12 weeks
showed fusion rates of 75%, 92%, and 83% for AG, BCPgranules and BCPputty, respectively. The
fusion rates were further increased 26 weeks postimplantation. Similar trends of bone growth
were observed by histomorphometry. The fusion mass consisted of at least 55% bone for all treat-
ment groups 26 weeks after implantation. These results suggest that this BCP with submicron sur-
face topography, in granules or putty form, is a promising alternative to autograft for spinal fusion.
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1 | INTRODUCTION
The annual number of spinal fusion procedures in the US for the treat-
ment of degenerative spine conditions has risen rapidly over the past two
decades to >770,000.1 The most commonly used spinal fusion technique
is posterolateral fusion (PLF), which is either performed as an individual
procedure (19%) or in combination with interbody cage fusion (45%).2
Because these procedures require large volumes of bone graft
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(12-36 cc),3 bone graft substitutes are frequently employed to reduce or
avoid morbidity related to the harvesting of autologous bone.4 Calcium
phosphate-based bone grafts have been widely investigated because of
their excellent biocompatibility, osteoconductivity and controllable resorp-
tion rate.5 A commonly addressed disadvantage compared to autologous
bone is their lack of osteogenic and osteoinductive capacity. However,
efforts to modify the physicochemical properties of calcium phosphates
(ie, composition, porosity and, most recently, surface properties) have
resulted in materials with bone-inducing properties. In particular, submi-
cron surface topographies have been reported to enhance angiogenesis
and bone healing properties following in vivo implantation.5–8
Surface properties of biomaterials have been shown to influence
the phenotype of macrophages,9–11 that are key modulators in the for-
eign body and wound healing responses.12,13 For promotion of bone
repair, an increase in anti-inflammatory macrophages following an initial
phase with pre-dominantly pro-inflammatory macrophages has been
suggested to be important.14,15 Recently, calcium phosphates with sub-
micron surface topography have been shown to promote the transition
of macrophages to the pro-healing, anti-inflammatory M2 phenotype
in vitro,8 which has been linked to enhanced angiogenesis and superior
bone healing properties observed with these materials.6,7
In the current study, a clinically relevant16–18 Ovine model of
instrumented PLF was used to compare treatment outcomes of a
biphasic calcium phosphate (BCP) with submicron surface topography
to bone autograft as a stand-alone treatment. The bone graft was
implanted as granules alone and as a putty, with granules embedded
in a fast-resorbing polymeric binder designed to improve handling
properties. Study endpoints included fusion rate by manual palpation,
range of motion (ROM), histology and histomorphometrical analysis of
bone in the fusion mass after 6, 12 and 26 weeks.
2 | METHODS
2.1 | Calcium phosphate
Commercially available BCP bone graft (MagnetOs; Kuros Biosciences
BV, Bilthoven, Utrecht, the Netherlands) was provided as granules
(BCPgranules) and putty (BCPputty). Both formulations contain 1 to
2 mm granules of bioactive bone graft comprising 65% to 75% Tri-
Calcium Phosphate (TCP—Ca3(PO4)2) and 25% to 35% Hydroxyapatite
(HA—Ca10(PO4)6 (OH)2). The carrier in the putty formulation is a tri-
block copolymer synthesized from polyethylene glycol (PEG) and L-
lactide monomer. The resulting polymer is water-soluble and dissolves
at near body temperature, leading to rapid dispersion after implanta-
tion (<48 hours).19 Scanning electron microscopy (SEM; JSM 5600,
JEOL) was used to characterize the submicron surface topography.
Bioactivity of the BCP surface was evaluated in vitro using the vali-
dated assay described by Kokubo et al.20 Briefly, the materials were
submerged in simulated body fluid (SBF) for 2, 4, 7, and 10 days and
subsequently analyzed for presence of an apatite-like-layer using
SEM. The materials for the animal study were provided sterile having
been sterilized by gamma irradiation (25 kGy).
2.2 | Animal study
The study design was based on a previously reported sheep model of
PLF18,21,22 and was approved by the local Animal Care and Ethics Com-
mittee (ACEC). Surgery was performed on 25 adult, female Merino sheep
(4-5 years, 80-90 Kg, at the University of New South Wales [UNSW],
Australia). Animals were randomly distributed into three groups for the
6, 12, and 26-week time-points, with an n of 8, 9, and 8, respectively.
Preoperative, animals were administered fentanyl (2 μg/kg/h, t.d.), bupre-
norphine (0.006 mg/kg, s.c.) and Carprofin (4 mL, s.c.) for pain relief and
Zoletil (8-12 mg/kg, i.m.) for induction. Anesthesia was achieved and
maintained by isoflurane (2%-4% in 100% O2). Surgery consisted of multi-
level instrumented spinal PLF procedure at levels L2-L3 and L4-L5. In
short, facet joints and transverse processes (TPs) were exposed followed
by destabilization of the motion segments and excision of the facet joints,
spinous processes and ligaments. TPs were decorticated after which the
operative levels were bilaterally instrumented with polyaxial pedicle
screws ( 5.0 × 35 mm) and titanium rods ( 5.5 mm, Wiltrom Co., Ltd.,
Zhubei City, Hsinchu County, Taiwan). Subsequently, 20 cc of graft mate-
rial was equally distributed to the bilateral arthrodesis sites in direct appo-
sition with each of the TPs (10 cc per side). The three graft materials were
iliac crest- and proximal tibia-derived (1:1) autologous bone graft (AG),
BCPgranules, and BCPputty, randomly allocated to the fusion levels (n = 5
for 6 and 26 weeks, n = 6 for 12 weeks). Postsurgery, the animals were
housed at the laboratory animal facility where they were monitored and
received proper postoperative care. After 6, 12, and 26 weeks, animals
were euthanized by IV injection of Lethotarb (1 mL/2 kg i.v., 325 mg/mL)
for analyses of endpoints.
2.3 | Manual palpation
After euthanasia, harvesting of the spines and removal of pedicle rods,
the L2-L3 and L4-L5 segments were manually subjected to flexion-
extension (FE) and lateral bending (LB) to assess spine mobility. All levels
were graded as either fused (low mobility), partially fused (one-sided
mobility) and not fused (high mobility) under FE and LB. The fisher-Free-
man-Halton Exact Test was performed for statistical analysis (P < 0.05).
2.4 | Micro-computed tomography
Micro-computed tomography (micro-CT) was performed using an
Inveon Scanner (Siemens Medical Solutions USA, Inc., Knoxville, TN,
USA) at a slice thickness of 50 μm.
2.5 | Biomechanical analysis
The treated levels were separately mounted on a robotic six degree of
Simulation Solutions Ltd., Stockport, UK freedom musculoskeletal sim-
ulator, simVITRO (Simulation Solutions Ltd., Stockport, UK and Cleve-
land Clinic Biorobotics Lab, Cleveland, OH, USA). A 7.5 Nm pure
moment was applied to the segments in FE, LB and axial rotation (AR).
Each loading profile was repeated three times for every specimen and
the mean angular deformation was recorded. Data were analyzed with
a two-factor ANOVA with a significance level of P < 0.05 using dedi-
cated software (Graphpad version 5). Normal distribution of data was
confirmed by Kolmogorov-Smirnov normality test.
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2.6 | Histology and Histomorphometry
The treated spine levels were fixed in 4% phosphate-buffered forma-
lin for 1 week at 4 Celsius. After fixation, samples were dehydrated
through a series of increasing ethanol concentrations and were subse-
quently embedded in methylmethacrylate. A Leica SP1600 saw-
microtome was used to cut sagittal cross-sections (10-20 μm) from
the region between TPs of each contralateral fusion mass. From each
sample, three sections were obtained across the fusion mass for eval-
uation. Sections were stained with 1% methylene blue and 0.3% basic
fuchsin to visualize bone tissue (bone matrix: pink, fibrous tissues:
blue). Sections were visualized under a Leica microscope (Eclipse 50i,
Nikon) for histological observation and were imaged using a slide
scanner (DiMage scan 5400 Elite II, Konica Minolta, Tokyo, Japan) to
obtain overviews for fusion assessment followed by histomorphome-
trical analysis. Each section was evaluated for histological fusion. His-
tological fusion was scored when a continuous presence of bone was
observed between the TPs, connecting the adjacent spine segments.
From each fusion mass, the most representative section was used for
histomorphometry. Histomorphometry of the fusion mass was per-
formed by pseudo-coloring pixels representing bone and remaining
implant material in a region of interest (Adobe Photoshop Elements
2.0). Values were expressed in mean and SD. For statistical evaluation,
a two-factor ANOVA was performed (P < 0.05). Normal distribution of
data was confirmed by D'Agostina-Pearson normality test.
3 | RESULTS
3.1 | Material characterization
Surface structure analysis of the porous BCP granules (Figure 1A)
by SEM demonstrated a surface topography of submicron-scale
polygon crystals (Figure 1B). Average surface crystal diameter was
determined to be 0.58  0.21 μm. Surface mineralization, evident
from the development of an apatite-like-layer of globules, was
FIGURE 1 (A) Porous BCP granule of 1-2 mm in size with (B) submicron surface topography of epitaxial polygon crystals. Submersion in SBF
resulted in the progressive formation of an apatite-like mineral layer on the material surface as shown by SEM after (C) 2 days, (D) 4 days,
(E) 7 days, and (F) 10 days
VAN DIJK ET AL. 3 of 10
observed in an increasing manner with time following submersion in
SBF (Figure 1B-F). These results confirm the bioactivity of the BCP
surface.
3.2 | Micro-computed tomography
Surgery and recovery proceeded without adverse events or adverse
reactions to the implant materials. After 6, 12, and 26 weeks, animals
were euthanized and the spine and surrounding tissues were har-
vested. Imaging by micro-CT showed that all graft materials were
well-contained at the implantation sites and there was progression to
a solid fusion mass between the spine segments over time (Figure 2).
At 26 weeks, mature fusion masses were evident and were indicated
by incorporation of the graft materials with host bone, and the inabil-
ity to discriminate individual BCP particles. Evaluation of fusion
masses suggested higher fusion mass volumes in the BCP groups at
12 and 26 weeks than with AG, indicating higher graft volume stabil-
ity with the BCP treatments.
3.3 | Manual palpation
Results of fusion assessment by palpation in a blinded manner are pre-
sented in Table 1. The data indicate a 100% fusion rate in each group
from 12 weeks onwards. No partially fused spines were found by
manual palpation. No statistically significant differences in fusion
between treatments at each time-point were determined (Fisher-
Freeman-Halton exact test, P ≥ 0.5).
3.4 | Biomechanical evaluations
ROM testing was performed to determine whether treatment
resulted in a reduction in mobility between the segments and thus a
higher stability, which is the primary goal of spinal fusion. Results of
ROM tests are presented in Figure 3. These results show decreasing
trends in ROM in LB, FE, and AR with no differences between
treatment groups. The decrease was strongest in LB for all mate-
rials, with an average decrease of 5.50  1.59 between 6 and
FIGURE 2 Examples of transversal micro-CT slices of the treated spine levels for AG (A-C) and BCP (D-F) at 6 (A, D), 12 (B, E) and 26 (C, F)
weeks. During time, consolidation of the fusion mass was evident for all treatments and gradual integration of graft materials with the underlying
host bone was observed. Graft volume at 12 and 26 weeks appear higher for BCP treatments than for AG, suggesting a higher graft volume
stability for BCP
TABLE 1 Fusion rate by manual palpation
Time-point AG BCPgranules BCPputty P value
a
6 weeks 3/5 1/5 1/5 0.50
12 weeks 6/6 6/6 6/6 0.99
26 weeks 5/5 5/5 5/5 0.99
a Fisher-Freeman-Halton exact test.
4 of 10 VAN DIJK ET AL.
26 weeks and statistical significance between 6 weeks and the later
time-points (two-factor ANOVA, P < 0.05). In FE, the average decrease
was 3.60  1.65 between 6 and 26 weeks, with significance for
AG and BCPputty, but not for BCPgranules. Although the data for AR
show a slight decrease in ROM of an average 1.67  1.03 between
6 and 26 weeks, statistical significance was not reached. No statisti-
cal differences between graft materials were seen in any loading
direction at any time-point, indicating equivalent spinal stability
between the positive control, autograft, and the treatment groups,
BCPputty and BCPgranules.
3.5 | Histology and histomorphometry
All further evaluations were performed by histology. Presence of a
bony fusion between the segments was assessed on sagittal cross-
sections of the fusion mass, as presented in Figure 4. The fusion
scores are given in Table 2. As the data show, fusion was rarely
observed at 6 weeks. However, a steep increase was observed for all
treatments at 12 weeks, with fusion rates of 75%, 92%, and 83% for
AG, BCPgranules and BCPputty, respectively. Specimens of the 26-week
endpoint showed a further increase in percentage of segments fused
with 90%, 100% and 90% for AG, BCPgranules and BCPputty, respec-
tively. Differences in fusion rate between treatments were not of sta-
tistical significance, indicating equivalent performance between the
three graft materials (Fisher-Freeman-Halton exact test, P ≥ 0.05).
High and low magnification histological sections were examined
to evaluate tissues within the fusion mass (Figures 4 and 5). Fibrous
tissue and blood vessel infiltration was complete in the central region
of the fusion at week 6 in all implants. In addition, bone formation
was observed near the host bone bed after 6 weeks in all groups. Dur-
ing the healing period, progression of bone tissue throughout the
fusion mass was observed, with an increased proportion of bone at
12 weeks and bone tissue occupying the full range of the fusion mass
after 26 weeks. Bone tissue was observed growing directly on BCP
material surface, with cuboidal osteoblasts colonizing the material sur-
face and secreting osteoid. Maturation of bone tissue in the fusion
mass was indicated by the transition from an early bone phenotype
FIGURE 3 Diagrams presenting ROM data of treated segments in LB (A), FE (B) and AR (C). Decrease in ROM over time was evident for each
loading direction, with no significant differences between groups. Symbols: # significantly different from AG, 6 weeks (P < 0.05); † significantly
different from BCPgranules, 6 weeks (P < 0.01); ‡ significantly different from BCPputty, 6 weeks (P < 0.05); • all significantly different from 6 weeks
(P < 0.001); ¤ significantly different from AG, 6 weeks (P < 0.01); § significantly different from BCPputty, 6 weeks (P < 0.05)
FIGURE 4 Sagittal histological sections (basic fuchsin-methylene blue) of spine levels grafted with AG or BCP, taken from the region between
the TP's. These sections were used to score spinal fusion, that is, the presence of a continuous bone bridge between the adjacent transverse
processes. The 6 weeks sections shown on the left were scored as “not fused” whereas 12 and 26 weeks shown in the center and right side were
scored as “fused”. Fusion by histology was frequently observed from 12 weeks onwards
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with abundant osteoid, woven bone and fibrous tissue towards a
mature bone phenotype at 26 weeks, characterized by a large propor-
tion of lamellar bone and bone marrow. Osteoclast-like multinu-
cleated phagocytes were observed phagocytosing the BCP material
indicating the cell-mediated resorption of the implanted material.
Gradual degradation of BCP granules was evident by the presence
of small particles of BCP separated from larger granules up to the
26-week time-point.
Histomorphometry data, represented in Figure 6, are consistent
with the general histological observation of the fusion mass. In all
groups, the proportion of bone in the fusion mass steadily increased
over time in a significant trend (P < 0.001), leading up to over 55% of
bone after 26 weeks. Between groups, at the 6-week time-point, a
higher proportion of bone was determined in the AG group
(25.2%  5.0) compared to BCPgranules (14.8%  7.1, P < 0.01) and
BCPputty (10.8%  5.9, P < 0.001), which can be explained by the
presence of autologous bone chips that were implanted at the fusion
site. After healing periods of 12 and 26 weeks, no differences in bone
volume were observed between all treatments (P > 0.05).
The proportion of BCP graft in the fusion mass was determined
for BCPgranules and BCPputty (Figure 6). As is evident from the graph, a
decrease in material volume was determined over time. In both BCP
groups, the amount of material in the fusion mass decreased by 25%
in the healing period from 6 weeks to 26 weeks, which was confirmed
by statistical analysis (P < 0.001). No significant difference in material
decrease between 6 and 12 weeks was determined for BCPgranules
and BCPputty. A slightly higher proportion of BCP graft in the fusion
mass was seen for BCPputty compared to BCPgranules at 6 weeks
(39.7  4.1% vs 33.2  5.7%, P < 0.01) and 26 weeks (29.9%  3.2
vs 24.9  5.0%, P < 0.05).
4 | DISCUSSION
The posterolateral spine environment is known to be challenging for
bone graft substitute materials because it provides very limited con-
tact with host bone from which bone growth can progress. In fact, a
successful lumbar arthrodesis is achieved by controlled bone
TABLE 2 Fusion rate by histology
Time-point
AG BCPgranules BCPputty
U B FR (%) U B FR (%) U B FR (%) P valuea
6 weeks 1/5 0/5 10 0/5 0/5 0 0/5 0/5 0 0.99
12 weeks 1/6 4/6 75 1/6 5/6 92 2/6 4/6 83 0.85
26 weeks 1/5 4/5 90 0/5 5/5 100 1/5 4/5 90 0.99
Abbreviations: B, bilateral fusion; FR, fusion rate; U, unilateral fusion.
a Fisher-Freeman-Halton exact test.
FIGURE 5 High magnification histology (basic fuchsin-methylene blue) of the grafts of levels treated with BCPgranules (A, C, E) and BCPputty (B, D,
F). Images show the progression and maturation of bone tissue from 6 weeks (A, B) to 26 weeks (C, D). Less mature bone tissue at 6 weeks is
recognized by the presence of abundant fibrous tissue (FT), osteoid (O) and woven bone (WB). New bone tissue was observed forming around
the BCP particles (BCP). At 26 weeks, more mature bone was recognized by the presence of lamellar bone (LB) and bone marrow (BM). Cuboidal
osteoblasts were observed depositing osteoid directly on the BCP granule surface (E, arrows, 6 weeks). In addition, large multinucleated cells
were observed resorbing the BCP material, with internalized fragments of material being apparent (F, arrows, 6 weeks)
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formation through the paraspinous soft tissues in between adjacent
TPs.23 Because of this, materials with physicochemical properties
designed to beneficially control the foreign body and wound healing
responses may be more effective bone graft substitutes for PLF, as
these can promote bone formation in sites distant from native bone
through mechanisms other than osteoconduction alone.
Although most commercially available bone grafts have under-
gone testing in lapine posterolateral fusion studies, only a handful
have been tested in higher-order animals such as sheep using poste-
rior pedicle screws and rods. Wheeler et al.24 compared BCP
(Mastergraft; 15% HA/85% β-TCP) and autograft, and reported 57.1%
and 100% fusion respectively at 16 weeks. Bone proportion in the
fusion mass at 16 weeks was significantly lower for the BCP
(36.2%  3.95) than for autograft (55.1%  7.59). In another work,
that studied macroporous BCP (MBCP; 65% HA/35% TCP), Guigui
et al.25 reported that this material achieved fusion after 12 months
while fusion by autograft was already observed after 6 months, as
was confirmed by biomechanical testing. A third study by Baramki
et al.26 reported high fusion rates for autograft and interconnected
porous HA after 20 weeks, but mechanical tests revealed poorer out-
comes for the HA group. In the absence of posterior fixation, β-TCP
alone has also shown inferior performance to autograft.27 Other stud-
ies have reported more favorable outcomes for ceramics compared to
autograft in this model,28–30 although certain limitations to those
studies are evident when compared to the current work. First of all,
fusion assessment by radiography (ie, X-ray and micro-CT) for evalua-
tion of calcium phosphate grafts is inconclusive and may lead to over-
estimations, because the high radiopacity of calcium phosphate limits
the ability to distinguish bone from material.31–33 Since the formation
of bone tissue is crucial for a successful spinal fusion, fusion assess-
ment by histology is a more accurate and reliable indicator than radio-
graphic assessment. Moreover, studies described in the prior art
lacked internal references for mechanical testing (eg, multiple time-
points) and reported equivalent spinal fusion with autograft or
ceramics at 16 weeks or later. Lastly, the age of the animal is often
reported as “skeletally mature” rather than the specific age or age
range. This is important, as fusion rates drop considerably for 5-year-
old ewes34 as compared to 2-3-year-old ewes,35 both of which are
skeletally mature. The 4 to 5 -year-old sheep used in the present
study present an additional relevant challenge for the graft to
overcome.
In the current work, by a combination of histological fusion data
and mechanical data (ie, manual palpation and ROM testing) at multi-
ple time-points, we demonstrated high spinal fusion success and
equivalence to autograft as early as 12 weeks post-surgery by this
BCP with submicron surface topography in both granule and putty
form. Both BCP formulations showed equivalent and sustained effi-
cacy for each endpoint, which indicates that the polymeric binder did
not inhibit bone-healing performance of the granules. This is in line
with expectations, since the binder was designed to rapidly dissolve
after implantation and consists of a biologically inert composition. By
histomorphometry at 6 weeks, levels treated with autograft showed a
slightly but significantly larger proportion of bone tissue in the fusion
mass, which may be explained by grafted autologous bone chips being
included in the measurement of newly formed bone. Although manual
palpation results suggest a higher fusion rate with autograft at 6 weeks
(nonsignificant), the ROM and histological fusion data indicate similar
healing progress between BCP treatments and autograft at the earli-
est time-point.
In comparison to previous studies, which show either an inferior-
ity of calcium phosphates compared to autograft or equivalence evi-
denced through weaker endpoints, we demonstrate equivalent
performance of AG, BCPgranules and BCPputty by an array of strong
assessment methods. In clinical literature, we can find conflicting
FIGURE 6 Diagrams presenting histomorphometry results of bone tissue (A) and BCP material (B) in the FM of the treated spine segments. Data
are presented as percentage of the available space in a region of interest. A linear increase of bone tissue in the fusion mass during time is evident
for all treatments (A). At 6 weeks, a slightly higher percentage of bone is shown for AG, but no differences were observed at later time-points.
A decrease in material percentage during time was observed for both BCP treatments (B). A slight difference between BCPgranules and BCPputty
is apparent at 6 weeks and 26 weeks. Symbols: * P < 0.01; ** P < 0.001; # all significantly different from 6 weeks, P < 0.001; † all significantly
different from 12 weeks and 6 weeks, P < 0.001; ‡ significantly different from BCPgranules, 6 weeks, P < 0.01; • significantly different from
BCPgranules, 26 weeks, P < 0.05
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evidence about the efficacy of calcium phosphate materials as bone
graft materials for spine fusion.36,37 Physicochemical properties of
biomaterials are rarely discussed in clinical literature and it is often
overlooked that these properties strongly influence the performance
of calcium phosphate bone graft materials. Indeed, during preclinical
in vivo studies, grafts with optimized physicochemical properties have
presented better outcomes than those with suboptimal properties.
For instance, calcium phosphate phase composition,38–43 macro-
porosity44–50 (ie, macro-pore size and interconnectivity) and bioactiv-
ity51 have been directly related to the in vivo tissue response, neovas-
cularization and bone-forming potential in ectopic and orthotopic
sites.40–43 Moreover, presence of a submicron surface topography
and micro-porosity has been linked to substantially enhanced bone-
inducing properties of calcium phosphates.6,7
One of the current hypotheses on the effectiveness of calcium
phosphates with submicron topography involves the polarization of
macrophages. Macrophages play a key role in the foreign body
response and their reaction to medical implants is pivotal for the suc-
cess or failure of an implant after implantation.52 Being of a plastic
nature, uncommitted macrophages can polarize towards a pro-
inflammatory phenotype (M1) or anti-inflammatory phenotype (M2) in
response to external triggers, including tissue damage or the implanta-
tion of a biomaterial.13,53 Studies have suggested that an increase in
anti-inflammatory M2 macrophages following an initial phase of
M1-dominated inflammation results in enhanced vascularization and
osteogenesis.14,15 Moreover, surface properties of biomaterials have
been demonstrated to influence macrophage phenotype after
implantation9–11 and recently, calcium phosphates with a submicron
surface topography were shown to promote the transition of macro-
phages to the M2 phenotype in vitro.8 The upregulation of M2 macro-
phages by submicron structured calcium phosphates may explain the
enhanced angiogenesis and superior bone healing properties observed
with these materials in vivo,6–8 as well as the results obtained in the
current work. However, the techniques used in the current study to
assess bone formation and spinal fusion were not designed for macro-
phage characterization. The proposed mechanism remains to be fur-
ther experimentally verified in future studies.
A limitation of the current study is that no materials with different
surface topographies were compared. Therefore, a recommendation
for future studies in this model is to include materials with no surface
topography or with surface topographies of different geometries and
dimensions (ie, supermicron scale), in order to isolate the effect of
material surface topography on graft efficacy. In addition, with regard
to mechanical testing, inclusion of a sham or “empty” control (ie, no
graft material) and baseline measurements immediately after surgery
would provide more insight on the effect of spinal fusion by these
graft materials on spine ROM.
We may conclude that this study provides solid evidence of the
adequate performance of a BCP with tailored physicochemistry as
stand-alone alternative to autograft in a clinically relevant Ovine model
of PLF. By application of reliable fusion assessment by histology and
supporting analyses at relevant time-points, we demonstrated a high
fusion rate after 12 weeks for this material, with overall equivalence
to autograft in fusion rate, mechanical integrity and bone formation
over the entire healing period of 26 weeks. These findings support
the premise that calcium phosphates with a submicron surface topog-
raphy are highly effective bone graft substitutes for PLF and this jus-
tifies further clinical investigation of these materials.
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